Ocean Biomedical Inc. has announced a significant regulatory setback following a final decision by the Nasdaq Stock Market LLC Board of Directors. The company was informed on July 31, 2025, that its appeal was denied, leaving the decision of the Nasdaq Listing and Hearing Review Council as the final action. This decision will lead to the removal of Ocean Biomedical's securities from listing, as per Nasdaq Rule 5820(e)(6). The delisting process will proceed in accordance with Nasdaq Rule 5830 and SEC Rule 12d2-2. Despite these challenges, Ocean Biomedical continues to advance its power and cryptocurrency strategies.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocean Biomedical Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-022271), on August 05, 2025, and is solely responsible for the information contained therein.